)
)
Lineage Cell Therapeutics Investor Relations Material
Latest events
Q3 2024
Lineage Cell Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Lineage Cell Therapeutics Inc
Access all reports
Lineage Cell Therapeutics, Inc., a biotechnology company, develops cell therapies for the treatment of degenerative diseases. The company develops allogeneic cellular therapies from immortally differentiated human cells. It is developing VAC, an allogeneic cancer immunotherapy for the treatment of solid tumors; OPREGEN, an allogeneic retinal pigment epithelial cell product for the treatment of dry age-related macular degeneration, as well as wet age-related macular degeneration and diabetic eye diseases; Neo-Kidney Augment, an allogeneic product candidate that is in preclinical study to treat subjects with end stage renal disease.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
LCTX
Country
🇺🇸 United States